Google and GSK invest £540M to create bioelectronic medicines

An early prototype concept for a smart contact lens. This wearable tech would measure glucose levels in tears, using a tiny wireless chip and miniaturised sensor embedded between layers of soft contact lens material. When glucose levels fall below a certain threshold, tiny LED lights will activate themselves to function as a warning system for the wearer. Credit: Google
Google's Verily (formerly Google Life Sciences) has announced a partnership with British pharmaceutical giant, GlaxoSmithKline (GSK), to form Galvani Bioelectronics – a new company focused on the research, development and commercialisation of bioelectronic medicines. Verily (owned by Google's parent company, Alphabet) has announced an agreement with GSK to form Galvani Bioelectronics to accelerate the research, development and commercialisation of bioelectronic medicines. GSK will hold a 55% interest in the new jointly owned company and Verily will hold 45%. Galvani Bioelectronics will be headquartered in the UK, with the parent companies contributing existing intellectual property rights and up to £540 million of investment over seven years, subject to successful completion of various discovery and development milestones. Bioelectronic medicine is a relatively new scientific field that aims to tackle a wide range of chronic diseases using miniaturised, implantable devices that can modify electrical signals that pass along nerves in the body, including irregular or altered impulses that occur in many illnesses. GSK has been active in this field since 2012 and believes certain chronic conditions such as arthritis, diabetes and asthma could potentially be treated using these devices. The agreement to establish Galvani Bioelectronics represents an important next step in GSK's bioelectronics research. It will combine GSK's world class drug discovery and development expertise, and deep understanding of disease biology, with Verily's world-leading technical expertise in the miniaturisation of low power electronics, device development, data analytics and software for clinical applications. The initial work will centre on establishing clinical proofs of principle in metabolic, inflammatory and endocrine disorders, including type 2 diabetes, where substantial evidence already exists in animal models; and developing the associated miniaturised, precision devices.

A chemical chip to control the delivery of the neurotransmitter acetylcholine. Credit: LiU/Ingemar Franzén

Moncef Slaoui, GSK's Chairman of Global Vaccines, who was instrumental in establishing GSK's investments in the field of bioelectronics, will chair the board of the new company: "Many of the processes of the human body are controlled by electrical signals firing between the nervous system and the body's organs, which become distorted in many chronic diseases," he said. "Bioelectronic medicine's vision is to employ the latest advances in biology and technology to interpret this electrical conversation and to correct the irregular patterns found in disease states, using miniaturised devices attached to individual nerves. If successful, this approach offers the potential for a new therapeutic modality alongside traditional medicines and vaccines."This agreement with Verily to establish Galvani Bioelectronics signals a crucial step forward in GSK's bioelectronics journey, bringing together health and tech to realise a shared vision of miniaturised, precision electrical therapies. Together, we can rapidly accelerate the pace of progress in this exciting field, to develop innovative medicines that truly speak the electrical language of the body." Brian Otis, Verily's Chief Technology Officer, said: "This is an ambitious collaboration, allowing GSK and Verily to combine forces and have a huge impact on an emerging field.Bioelectronic medicine is a new area of therapeutic exploration, and we know that success will require the confluence of deep disease biology expertise and new highly miniaturised technologies. "This partnership provides an opportunity to further Verily's mission by deploying our focused expertise in low power, miniaturised therapeutics and our data analytics engine to potentially address many disease areas with greater precision with the goal of improving outcomes." Since 2012, a dedicated team of scientists at GSK has been researching the potential of bioelectronic medicines. In that time, the company has established a leadership position in the field, creating a global network of around 50 research collaborations and investing $50 million in a dedicated bioelectronics venture capital fund. Through these collaborations and investments, GSK has seen encouraging proof of principles in animal models in a range of diseases. GSK believes the first bioelectronic medicines could be ready for approval within the next decade. Source: http://www.futuretimeline.net/

Read More........→August 23, 2016

Google files patent for wearable medical device

Google has filed a patent application for a wearable medical device, able to use nanoparticles to detect and treat illnesses such as cancer.

For those wishing to protect their health and extend their lifespan, a futuristic medical device may become available in the next several years. Details of this wearable technology – known as a Nanoparticle Phoresis – have been published online by Google, via the World Intellectual Property Organisation. The patent application describes a strap, or band, mounted on the lower arm. Similar in appearance to a wristwatch, it would "automatically modify or destroy one or more targets in the blood that have an adverse health effect." This would be achieved by beaming energy into blood vessels to stimulate cells and molecules, increasing their effectiveness at fighting diseases. It could even be used on synthetic nanoparticles. Millions of these tiny objects would be introduced into the wearer's bloodstream, then activated by magnets in the wristband and directed to specific locations. In addition to its physical treatment abilities, the Nanoparticle Phoresis could generate vast amounts of data – not only helpful to the user, but also to researchers and doctors. It could accept inputs from the wearer regarding his or her health state, such as "feeling cold," "feeling tired," "pollen allergy symptoms today," "stressed," "feeling energetic," etc. According to the patent, these user inputs "may be used to complement any other physiological parameter data that the wearable device may collect and establish effective signal levels for and timing of modification of the target." Analysts forecast that wearable technology will see huge growth in the coming years, with unit sales potentially reaching into the

hundreds of millions. This new device from Google – if successfully developed – could become part of that rapidly evolving ecosystem. Initially aimed at patients who are seriously ill, this product (or its derivatives) could also be offered to mainstream consumers who aren't necessarily in bad health, but wish to monitor and improve their well-being. For those with a needle phobia, injections might be possible using high-pressure jets. Although the patent itself makes no mention of this, we can speculate that such a procedure would eventually be incorporated into a wristwatch form factor. Similar to the "hypospray" on Star Trek, these jets would ensure that the skin is not punctured. High-pressure jet injection was covered on our blog in May 2012. Looking further ahead, the prospects become even more exciting. Bill Maris – who helped form Google Calico – this month stated his belief that humans will live to be many centuries old in the future, while today's cancer treatments will seem "primitive" within just 20 years. His comments echo those of futurist and inventor Ray Kurzweil, also employed at Google and currently involved in AI research for the company. Kurzweil predicts that nanoparticles will be superseded by nanobots – small and compact enough to feature motors, sensors and other tools, allowing them to be controlled with extreme precision directly inside cells. If this idea sounds like science fiction, then consider this: a handheld smartphone today contains more processing power than a room-sized supercomputer of the 1980s. With ongoing advances in miniaturisation, together with new materials such as graphene, the future trend seems inevitable. As humans become ever more dependent on technology, our bodies will gradually begin to incorporate these and similar devices on a permanent basis. Later in the 21st century, the line between man and machine could become blurred. Source: Article

Read More........→February 15, 2016